Fenamic

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fenamic

What is Fenamic? Defining the Medicine

Property Description
Active Ingredient Mefenamic Acid
Form Oral Capsule / Film-coated Tablet
Pharmacological Class Nonsteroidal Anti-Inflammatory Drug (NSAID)
General Purpose Relief from Pain, Inflammation, and Fever
Origin Synthetic Organic Compound (Anthranilic Acid Derivative)

Fenamic is a medicine whose active component is the drug substance Mefenamic Acid, which is a synthetic organic compound derived from anthranilic acid. Mefenamic Acid is formally classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). It specifically belongs to the Fenamate chemical group, positioning it distinctly within the broader category of pain-relieving agents. This chemical identity characterizes its efficacy profile in treating acute discomfort.


The medication is supplied for patient use as a solid dosage form, typically an oral capsule or a film-coated tablet, suitable only for oral administration. Unlike some NSAIDs that may be available in topical formulations, Fenamic is designed for systemic action upon ingestion. The primary therapeutic purpose of Fenamic is to offer broad, systemic symptomatic relief by employing a triple action of effects. This involves delivering an analgesic (pain-relieving) action, providing an anti-inflammatory effect to mitigate swelling, and executing an antipyretic effect to help normalize elevated body temperature. This defined formulation and mechanism underpin its overall role in mitigating acute discomfort involving these three common symptoms.

Regulatory References

  1. NIH/NCBI LiverTox - Mefenamic Acid
  2. MedlinePlus Drug Information - Mefenamic Acid

What side effects are possible with Fenamic?

Possible Side Effects and Safety Information

The safety profile of Fenamic (Mefenamic Acid) is based strictly on regulatory documents from governmental authorities, defining officially listed adverse reactions and safety constraints.

Serious Safety Warnings

Official labeling includes serious warnings regarding potentially fatal adverse events, primarily affecting the cardiovascular and gastrointestinal systems:

  • Cardiovascular Thrombotic Events: An increased risk of serious events, including Myocardial Infarction (MI) and Stroke, is documented. This risk may increase with duration of use.
  • Gastrointestinal Events: A heightened risk of serious gastrointestinal inflammation, bleeding, ulceration, and perforation is listed. These events can occur without prior warning symptoms.

Officially Documented Adverse Reactions

Adverse reactions are classified by the body system affected:

System-Organ Class (SOC) Examples of Common Reactions Examples of Rare Reactions
Gastrointestinal Diarrhea, Nausea, Abdominal pain Ulceration, Perforation
Nervous System Headache, Dizziness Convulsions
Skin Rash, Pruritus Stevens-Johnson Syndrome (SJS)

Safety Constraints and Special Populations

Fenamic is subject to specific regulatory limitations:

  • Contraindications: Use is contraindicated for managing peri-operative pain after Coronary Artery Bypass Graft (CABG) surgery. It is also contraindicated in patients with severe heart, liver, or kidney failure.
  • Older Adults: This population has an increased frequency of adverse reactions, particularly serious and potentially fatal gastrointestinal bleeding.
  • Pregnancy: Use after 20 weeks of pregnancy is associated with risks of fetal heart or kidney problems.

Overdose and Emergency Response

Fenamic Overdose and when to seek help is governed by specific regulatory guidelines that address documented toxicity and required emergency response.

Documented Overdose Manifestations

System Affected Official Regulatory Manifestations
Central Nervous System (CNS) Convulsions (seizures) are a prominent feature, often preceded by agitation, twitching, lethargy, drowsiness, or disorientation. Loss of consciousness (coma) has been reported [NIH MedlinePlus].
Gastrointestinal (GI) Symptoms commonly include nausea, vomiting, abdominal pain, and epigastric distress. Severe GI bleeding, such as bloody vomit or black, tarry stools, may also occur [NIH MedlinePlus].
Systemic/Renal The overdose profile includes a risk of acute organ impairment, specifically acute renal failure (acute kidney injury), and metabolic acidosis has been reported in severe cases [NIH/PMC].

Required Emergency Actions

The regulatory guidance is uniform: Seek immediate medical attention right away for any suspected overdose. Call emergency services immediately if the person is showing severe symptoms, such as having a seizure, experiencing trouble breathing, collapsing, or being unable to be awakened [NIH MedlinePlus].

Official Management Constraints

The official labeling states that no specific antidote is known for acute NSAID toxicity. Management is strictly confined to symptomatic and supportive treatment, including observation for at least 12 hours. Monitoring of renal function and management of CNS effects are critical components of care [FDA/NPIS].

Therapeutic Uses of Fenamic

What Fenamic Treats: Main Uses and Benefits

Fenamic (Mefenamic Acid) is applied across therapeutic domains where additional symptomatic support is needed to address discomfort and associated physiological symptoms. It may assist with addressing symptom clusters that become intense or disruptive. The medication is relevant for managing mild to moderate pain and is commonly used for primary dysmenorrhea.

The medication is commonly used across conditions presenting with acute episodes where symptoms may intensify temporarily, such as headaches, acute dental pain, general musculoskeletal discomfort, and the pain of rheumatoid or osteoarthritis flares. A distinct application is for managing the pronounced cramping pain of primary dysmenorrhea and abnormally heavy menstrual bleeding (menorrhagia). Fenamic is also applied in clinical settings that involve acute or unstable symptom patterns, such as managing post-operative and postpartum pain.

“It provides supportive relief when symptoms interfere with routine activities, helping patients cope more steadily with symptom fluctuations.”

This approach may contribute to maintaining functional stability by providing symptomatic relief when discomfort becomes more noticeable.


Quick Fact: Relief for Menstrual Cramps

Fenamic may assist with easing the pronounced discomfort and heavy bleeding associated with the menstrual cycle.

Regulatory References

  1. NIH DailyMed drug monograph

Eligibility and Restrictions for Use

Fenamic (Mefenamic Acid) is an NSAID (Nonsteroidal Anti-inflammatory Drug) typically used for pain and inflammation, but its use is restricted for certain individuals to ensure safety.

Who Can Use Fenamic?

Generally, Fenamic is prescribed to adults and adolescents over 14 years old for conditions such as:

  • Acute mild to moderate pain (e.g., dental, muscular).
  • Primary dysmenorrhea (menstrual pain).

Who Cannot Use Fenamic (Contraindications)?

Fenamic should not be used by individuals with certain pre-existing conditions due to the risk of serious adverse effects. Contraindications include:

  • Active or recurrent peptic ulcer/gastrointestinal bleeding.
  • Severe renal or hepatic impairment.
  • Severe heart failure.
  • A history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.
  • The third trimester of pregnancy.

Always consult a healthcare provider to determine if Fenamic is appropriate for your specific health profile.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Fenamic's official regulatory documentation identifies several clinically significant interactions with other medicinal products and substance categories. These interactions are primarily based on effects on bleeding risk, renal function, and drug metabolism/absorption.

Category of Interacting Product Regulatory Constraint/Effect
Oral Anticoagulants (e.g., Warfarin) Increased risk of bleeding; requires continuous monitoring of prothrombin time due to displacement from plasma proteins.
Antiplatelet Agents (e.g., Low-Dose Aspirin) May interfere with the anti-platelet effect of aspirin.
Other Systemic NSAIDs Concomitant use with other non-aspirin NSAIDs, including COX-2 inhibitors, should be avoided due to the increased risk of adverse events.
Diuretics / Antihypertensives (ACE-I, ARBs) May reduce the therapeutic effectiveness of these medications; increases the risk of renal adverse events, especially in the elderly or volume-depleted patients.
Lithium Can significantly increase plasma Lithium concentrations by reducing its renal clearance, requiring careful monitoring for toxicity.
Magnesium-Containing Antacids Increases the rate and extent of Fenamic absorption, which may lead to enhanced systemic exposure.

Fenamic is metabolized by the CYP2C9 enzyme; therefore, individuals who are poor CYP2C9 metabolizers may experience higher plasma levels. This interaction profile mandates specific restrictions, including the contraindication for use in the peri-operative setting of coronary artery bypass graft (CABG) surgery.

Mechanism of Action

Fenamic (a fenamic acid derivative, such as Mefenamic acid) is a type of non-steroidal anti-inflammatory drug (NSAID) whose action results from its impact on the arachidonic acid cascade.

Inhibiting Prostaglandin Synthesis

This mechanism involves Fenamic acting as a non-selective competitive inhibitor of the Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) enzymes. By binding to the active site, the drug blocks the conversion of arachidonic acid into prostanoids, which are key physiological mediators.

Modulation of Signaling Pathways

Reducing the level of inflammatory prostaglandins, particularly PGE2, disrupts several key physiological responses. This suppression results in decreased sensitization of peripheral nociceptors and a re-setting of the hypothalamic thermoregulation set-point.

COX-1 Inhibition and Homeostasis

The non-selective mechanism, which involves inhibiting the constantly active COX-1 enzyme, also modulates homeostatic functions. This affects the synthesis of regulatory prostanoids, such as those that maintain gastric mucosal integrity and those that promote platelet aggregation.

Dosage and Administration Information

How to Use Fenamic (Mefenamic Acid) — Administration Guidelines

Fenamic is for oral administration (capsule, tablet, or suspension) and must be taken with or immediately after food or with a full glass of water to minimize gastrointestinal upset. The dosing guidelines involve using the lowest effective dose for the shortest duration necessary to manage symptoms.


Dosing and Scheduling

Administration Scope Adult (Oral Dosage Form) Age-Group Administration Rules
Initial Dose 500 mg (once) Pediatrics: Not recommended for patients less than 14 years of age.
Maintenance Dose 250 mg every 6 hours, as needed. Children: Suspension may be used for those over 6 months of age, dosed at 25 mg/kg of bodyweight daily in divided doses.
Maximum Duration Usually no more than 7 days (acute pain) or 2-3 days (dysmenorrhea). Geriatric: The lowest effective dose should be used for the shortest possible duration.

Procedural Steps and Missed Dose Instructions

Special Procedural Conditions:

  • For painful menstrual symptoms (dysmenorrhea), treatment should commence at the onset of bleeding or associated pain.
  • The use of alcohol during therapy is to be avoided.

Missed Dose Rules:

If a dose is missed, the patient should take it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule should be resumed. A patient must not take a double dose to compensate for the missed one.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Fenamic

Evidence for use in Chronic Low Back Pain

Research examined Fenamic in relation to chronic low back pain, a condition characterized by functional limitations. Research explored primarily short-term randomized controlled trials (RCTs) and small observational cohorts. These studies focused on measuring patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning or activity level in adults with non-specific, long-lasting back pain.

The available research highlights changes measured during the study period, which typically lasted between 4 and 12 weeks. Findings describe patterns observed in the studies related to short-term symptom changes. The evidence is limited and findings were mixed across the different study groups that research examined.


Evidence for use in Fibromyalgia

Studies monitored symptom patterns in adults diagnosed with fibromyalgia, a condition marked by functional limitations and symptoms that may vary in intensity. The studies conducted were generally short-to-medium-term randomized controlled trials. Research explored outcomes related to physical discomfort, sleep quality, and the overall impact on daily functioning.

Studies report how symptoms evolved in the observed populations. Research highlights changes measured during the study period, but the reported effects were modest. This evidence contributes to understanding symptom patterns but certainty remains low.


Evidence for use in Chronic Regional Pain Syndrome (CRPS) Type 1

Research examined CRPS Type 1 in a limited number of small, short-term studies using Fenamic. These studies were generally small and short-lived, with research exploring short-term symptom changes, primarily by measuring outcomes related to physical discomfort.

Studies help show what has been observed so far, which were measurements of short-term changes in reported pain intensity. The evidence is limited and based on very small study populations.


What is still uncertain about Fenamic

Across all studied conditions, the certainty remains low due to several research limitation frames, including that sample sizes were modest and that evidence quality varies across studies. Furthermore, long-term effects are not fully established. Research is ongoing to better understand symptom patterns. Findings describe group patterns, not personal outcomes.

Key Studies & References

  1. Analgesic effects of non-surgical and non-interventional treatments for low back pain: a systematic review and meta-analysis of placebo-controlled randomised trials
  2. Effect of pharmacotherapy on fibromyalgia: an overview of systematic reviews
  3. Mefenamic Acid: MedlinePlus Drug Information (Regulatory/Guidance Context)

Frequently Asked Questions (FAQ)

Common questions about Fenamic (FAQ)


Q: Does Fenamic have a long half-life compared to similar drugs?

Official regulatory information on Fenamic, which contains Mefenamic Acid, indicates that it has a relatively short elimination half-life. The time required for half the drug to leave the body is approximately two to four hours in adults.


Q: Can children or teenagers take Fenamic for pain relief?

The US FDA label generally does not include recommendations for patients less than 14 years of age. However, some international product guidelines mention the use of a suspension formulation for children over six months old, when prescribed under strict medical guidance.


Q: Do you need a prescription to get Fenamic?

According to official regulatory designations, Fenamic is generally classified as a prescription-only medicine in many regions. This means that a valid prescription from a licensed healthcare provider is typically required to obtain it.


Q: What happens if you miss a dose of Fenamic?

If a dose is missed, the regulatory instructions state the dose can be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped and the regular schedule should be resumed. Official guidance states that a double dose must not be taken to compensate for a missed dose.


Q: How long does Fenamic stay in your system after the last dose?

The time it takes for Fenamic to be cleared from the bloodstream is relatively short, based on its elimination half-life of two to four hours. The drug and its inactive byproducts are primarily excreted by the body through urine and feces.


Q: Does Fenamic interact with birth control pills?

Regulatory-derived information indicates that there is a potential for interaction between Fenamic and certain types of oral contraceptives. For example, some combinations may increase the risk of elevated potassium levels, and the interaction profile may require specialized monitoring.


Q: Why is it important to take Fenamic with food?

Taking Fenamic with or immediately after food or a full glass of water is officially recommended. This helps to reduce the risk of gastrointestinal side effects, such as stomach upset and irritation, which are known risks associated with this class of medication.


Q: Is Fenamic generally considered a strong or mild pain reliever?

Based on its official regulatory indications, Fenamic is approved for the relief of acute mild to moderate pain. This classification helps set the expectation for the level of symptomatic relief it is designed to provide.


Q: Can Fenamic be crushed or split if it's a tablet?

Fenamic is often supplied as an oral capsule or a film-coated tablet. Regulatory information indicates that crushing or splitting these forms is generally not recommended as it may alter the medication's intended release properties or absorption rate within the body.


Q: How quickly should Fenamic start working for inflammation?

Fenamic is rapidly absorbed after ingestion, typically reaching its highest concentration in the bloodstream within two to four hours. The drug’s rapid absorption profile supports the official guidance for painful menstrual symptoms, where treatment is often initiated at the onset of pain.


Q: What is the chemical or scientific name for Fenamic?

The medication known as Fenamic is a product that contains the active ingredient Mefenamic Acid. This is the formal scientific name for the drug substance responsible for the medication's therapeutic effects.


Q: What are the most common reasons people stop taking Fenamic?

Adverse event data indicates that the most common reasons for discontinuing treatment are usually linked to gastrointestinal side effects. Diarrhea, in particular, has been reported in clinical studies as a side effect that may lead to the medication being stopped.


Q: Can Fenamic affect liver function test results?

The official product labeling notes that some patients may show borderline elevations in one or more liver function test results. These changes are often described as being transient or may remain relatively stable even with continued therapy.


Q: Is Fenamic the same as Mefenamic Acid?

Yes, Fenamic is a product or brand name that contains the active drug substance Mefenamic Acid. Therefore, the medication’s pharmacological actions and therapeutic effects are due entirely to Mefenamic Acid.


Q: What research supports the use of Fenamic for menstrual pain?

Fenamic (Mefenamic Acid) is officially approved and indicated for the treatment of primary dysmenorrhea (painful menstruation). This indication is supported by clinical trials and efficacy data submitted to and reviewed by regulatory authorities.


Q: Can Fenamic interact with common over-the-counter cold medicines?

Official regulatory warnings advise caution when combining Fenamic with other non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs). Since many over-the-counter cold medicines contain other NSAIDs, combination use is generally discouraged due to the increased risk of adverse events.


Q: What's the typical duration someone takes Fenamic for an acute injury?

Regulatory guidance requires the use of the lowest effective dose for the shortest possible duration when treating acute pain. Specifically, for acute pain management, treatment should generally last no more than seven days.


Q: Are there different strengths or dosages of Fenamic available?

Fenamic is commonly available in a 250 mg strength and a 500 mg strength for the initial adult dose. In addition to these capsule or tablet forms, a liquid suspension formulation is also available in some regions.


Q: What percentage of users report side effects with Fenamic?

Official clinical trial data reports on the incidence of serious side effects. For instance, symptomatic upper gastrointestinal ulcers, gross bleeding, or perforation were reported to occur in approximately one percent of patients treated for three to six months in those studies.


Q: Does Fenamic have an effect on stomach lining protection?

Fenamic works by inhibiting the COX-1 enzyme, which is involved in creating protective substances that maintain the integrity of the gastric mucosal lining. Interfering with this process is the mechanism that links Fenamic to its potential gastrointestinal side effects.


Q: What conditions does Fenamic help with that aren't pain-related?

In addition to addressing pain and inflammation, Fenamic is officially indicated for its antipyretic effect. This means it has a documented use in helping to reduce or manage an elevated body temperature (fever).


Q: Is the onset of action different for the liquid form of Fenamic?

Regulatory information indicates both solid (capsule/tablet) and liquid (suspension) forms are available. Comparative data on the difference in speed of action between formulations is not always included in general regulatory summaries.


Q: Does Fenamic cause or worsen heartburn?

Yes, heartburn is an adverse reaction that is explicitly documented in the official safety information for Fenamic (Mefenamic Acid). It is listed as a possible side effect alongside other common gastrointestinal issues like nausea and dyspepsia.


Q: Is Fenamic known to cause insomnia or sleep disturbances?

The official labeling does list certain central nervous system (CNS) effects. Regulatory advisories for NSAIDs generally include sleep disturbances like insomnia in their broader list of possible, though less common, adverse events.


Q: How soon after taking Fenamic can you take another type of pain reliever?

Official regulatory guidance states that Fenamic should not be taken simultaneously or concurrently with any other non-aspirin non-steroidal anti-inflammatory drug (NSAID). Fenamic has its own specific dosing schedule, which should be followed as prescribed.

How should Fenamic be stored and disposed of?

How to Store and Dispose of Fenamic?

Regulatory authorities require that Fenamic (Mefenamic Acid) be stored under specific environmental conditions to maintain its stability. The medication must be kept at a controlled room temperature, typically not exceeding 30 C (86 F), and must be protected from excessive heat and moisture.

Storage and Protection

The product should be stored in the original, tightly closed container and must be kept strictly out of the sight and reach of children.

Disposal Requirements

Fenamic should not be disposed of via household waste or wastewater. Unused or expired medication must be discarded according to local regulatory procedures or by utilizing an authorized drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fenamic found in:

A-Z Index: